Case Overview

Article Type: Roundup | Vertical: Dangerous & Defective Drugs / Consumer Protection

Published: March 2026 | Cases Covered: 3

Key Topics: Compounded semaglutide false advertising, BMW vehicle recall, Canadian oyster recall

GLP-1 False Advertising Claims, a Vehicle Fire Risk, and a Norovirus Oyster Recall: What Consumers Need to Know This March

Three new consumer safety developments emerged this week — including a class action lawsuit targeting a major telehealth company's compounded weight loss drugs. Here's a look at what's been filed and recalled, and what it may mean for affected consumers.

1. Hims & Hers Semaglutide Products Allegedly Misrepresented to Consumers

Filed: March 2026

Who May Be Affected: Consumers who purchased compounded semaglutide GLP-1 products from Hims & Hers

Claim Type: False advertising, consumer protection

According to a recent class action complaint filed against Hims & Hers, the telehealth company allegedly misled consumers by marketing its compounded semaglutide products as equivalent to the brand-name weight loss and diabetes medications Ozempic and Wegovy.

The lawsuit alleges that Hims & Hers falsely advertised these compounded GLP-1 products in a way that would lead reasonable consumers to believe they were purchasing the same formulation as the FDA-approved brand-name drugs. According to the complaint, that is not the case — compounded semaglutide is not FDA-approved and is not required to meet the same manufacturing standards as its brand-name counterparts.

The plaintiff claims that had consumers known the products were not equivalent to Ozempic or Wegovy, they would not have purchased them — or would have paid significantly less.

Compounded semaglutide products became widely available during a period when Ozempic and Wegovy faced significant supply shortages. The FDA permitted compounding pharmacies to produce semaglutide during that shortage window, but has since signaled that the shortage has been resolved — raising regulatory questions about the continued sale of compounded versions.

What this means for consumers: Those who purchased compounded semaglutide products from Hims & Hers may want to monitor this litigation for developments. No settlement has been reached, and the case is in early stages.

2. BMW Recalls Nearly 60,000 Vehicles Over Potential Fire Hazard

Announced: March 13, 2026

Vehicles Affected: BMW M5, 5 Series, 7 Series, i5, i7, and M5 luxury models (approximately 58,000 vehicles)

Hazard: Potential fire risk linked to air conditioning system wiring

BMW has issued a recall for more than 58,000 vehicles due to a potential fire hazard connected to the wiring harness in the air conditioning system, according to the recall announcement. The affected vehicles include several of BMW's premium and performance lines: the M5, 5 Series, 7 Series, i5, i7, and M5 luxury models.

The recall does not involve a class action filing at this time, but vehicle recalls of this nature can form the basis for future litigation if consumers experience property damage or injury before a repair is completed.

What this means for consumers: Owners of the listed BMW models may want to check whether their vehicle falls within the recall by visiting the NHTSA vehicle recall lookup tool using their VIN number. Recalls are typically remedied at no cost through authorized dealerships.

3. Canadian-Harvested Oysters Recalled Over Norovirus Contamination Risk

Announced: March 12, 2026

Products Affected: Raw oysters harvested in Canada and distributed by Stellar Bay Shellfish

Hazard: Potential norovirus contamination

The U.S. Food and Drug Administration and Stellar Bay Shellfish have jointly announced a recall of raw oysters harvested in Canada due to concerns about potential norovirus contamination, according to the recall notice. Norovirus is a highly contagious illness that can cause vomiting, diarrhea, and stomach cramping, and is commonly associated with raw shellfish consumption.

The FDA's involvement signals the recall extends to products distributed across U.S. markets. Consumers who purchased raw oysters from Stellar Bay Shellfish are encouraged to check the FDA's current recall database for specific lot numbers, harvest dates, and distribution details.

What this means for consumers: Anyone who has recently consumed raw oysters and is experiencing gastrointestinal symptoms should consider consulting a healthcare provider. This article is for informational purposes only and does not constitute medical advice.

Key Takeaways

• The Hims & Hers semaglutide lawsuit reflects a broader legal trend — as compounded GLP-1 products face increased regulatory scrutiny, consumer protection litigation is likely to grow. Consumers who purchased these products based on comparisons to Ozempic or Wegovy may want to follow this case closely.
• Recalls don't always lead to lawsuits, but unresolved safety defects in consumer products — including vehicles — can form the basis for future litigation if injuries occur before repairs are made.
• Food recalls can move quickly. The oyster recall was announced just one day after the Hims & Hers lawsuit filing, a reminder that multiple consumer safety issues can emerge in a short window. Checking the FDA's recall database regularly is a straightforward way to stay informed.
• Compounded drugs occupy a complex regulatory space. FDA approval of a brand-name drug does not extend to compounded versions — a distinction that sits at the heart of the Hims & Hers lawsuit.

Have you purchased compounded semaglutide products, owned one of the affected BMW models, or purchased Stellar Bay oysters recently? Share your experience in the comments below.

This article is for informational purposes only and does not constitute legal or medical advice. Consult a qualified attorney to understand your legal options, and speak with your doctor before making any changes to your medication.